Miflonil Breezhaler (Budesonide)

Budesonide, the active ingredient in Miflonil Breezhaler, is a corticosteroid presented as an inhalation powder for inhalation use. It reduces airway inflammation and is indicated for the management of asthma and chronic obstructive pulmonary disease in appropriate patients. It is formulated for delivery via the Breezhaler device, providing consistent dose distribution and rapid onset of action.

GNH USA supplies Miflonil Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and supports regulatory compliance for importers.

Budesonide is an inhaled corticosteroid that acts on airway inflammation in respiratory disease.

- Asthma: Improves symptom control and reduces frequency of exacerbations. - COPD: Decreases exacerbation risk and enhances lung function. - Bronchial hyperresponsiveness: Reduces airway hyperreactivity in patients with asthma.

Budesonide may cause a range of adverse reactions when inhaled.

Common Side Effects: - Oral thrush (candidiasis) - Hoarseness or dysphonia - Throat irritation - Cough

Serious or Rare Side Effects: - Adrenal suppression - Pneumonia - Paradoxical bronchospasm

When prescribing or using Miflonil Breezhaler, consider the following precautions.

- Assess inhaler technique: Ensure patient demonstrates correct use of the Breezhaler device. - Monitor for oral candidiasis: Advise rinsing mouth after each inhalation. - Evaluate adrenal function: Particularly for long‑term high‑dose therapy. - Use lowest effective dose: To minimise systemic exposure. - Caution in patients with active infections: Inhaled steroids may increase infection risk. - Store at room temperature: Keep in original container, protect from moisture.

Budesonide may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase systemic budesonide exposure. - Live attenuated vaccines: Reduced vaccine efficacy and increased infection risk. - Systemic corticosteroids: Additive systemic glucocorticoid effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): May modestly raise budesonide levels. - Ritonavir: Can increase systemic exposure. - Theophylline: May have altered plasma concentrations.